Health Canada Authorizes Mirum's LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial ...

Health Canada has authorized Livmarli (maralixibat) oral solution and tablet formulation for the treatment of cholestatic ...

Research indicates that many statin therapy side effects are not supported by evidence, suggesting a need for revised ...

Parenteral nutrition (PN)-associated cholestasis (PNAC) is frequently diagnosed in premature infants; however, not all PN-exposed infants develop PNAC. We propose that, in premature infants receiving ...

Mirum Pharma receives Health Canada authorization for maralixibat to treat cholestatic pruritus in patients with Alagille syndrome: Toronto Saturday, February 7, 2026, 15:00 Hrs [ ...

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) shares dipped Thursday. The company, treating rare diseases company, announced that Health Canada has authorized LIVMARLI® (maralixibat) oral solution and ...

Mirum Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in ...

There is a lot of interaction between pregnancy and skin changes, says Dr Nirmala M, a gynaecologist and fertility specialist ...

Primary biliary cholangitis (PBC) is a rare chronic autoimmune cholangiopathy that mainly affects middle-aged women, ...

DelveInsight's Primary Sclerosing Cholangitis Market Insights report includes a comprehensive understanding of current ...

ATP-binding cassette (ABC) transporters are transmembrane proteins essential for the biliary secretion of bilirubin, bile acids, phospholipids, and ...

Mirum Pharmaceuticals acquires Bluejay Therapeutics, focusing on brelovitug for chronic hepatitis delta virus (HDV), a severe ...